| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Ig alpha-1 chain C region;IGHA1; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human DDAH2 Hydrolyzes N (G),N (G) -dimethyl-L-arginine (ADMA) and N (G) -monomethyl-L-arginine (MMA) which act as inhibitors of NOS. Has therefore a role in the regulation of nitric oxide generation. |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-DDAH2 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone AEGG-4; isotype Rabbit IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB, IP (as provided in the source record). Boster Bio Anti-DDAH2 Monoclonal Antibody catalog # M07566. Tested in WB, IP applications. This antibody reacts with Human, Mouse, Rat.
Key elements and design rationale
- Target: DDAH2 (Ig alpha-1 chain C region).
- Antibody format: Monoclonal; clone AEGG-4; isotype Rabbit IgG.
- Host: Rabbit.
- Species reactivity: Human,Mouse,Rat (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
DDAH2 (protein: T-cell surface glycoprotein CD3 zeta chain) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Ig alpha is the major immunoglobulin class in body secretions. It may serve both to defend against local infection and to prevent access of foreign antigens to the general immunologic system. Reported cellular localization context: Nucleus . Tissue expression notes (as provided): Brain.
Research relevance and current trends
- Research context keywords from the source record include: Neuroscience,Neurotransmission.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
- Immunoprecipitation (IP): enrich target complexes for downstream immunoblot or interaction analyses.
Workflow ideas (metafield): Validate DDAH2 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect DDAH2 expression by Western blot in cell or tissue lysates, Enrich DDAH2 by immunoprecipitation from lysates for downstream analysis
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 22 kDa; calculated MW: 37655 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 22 kDa
- Cellular localization (provided): Nucleus .
- Tissue details (provided): Brain.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
